Business ❯ Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

Novo Nordisk Eli Lilly Wegovy GLP-1 Drugs Market Competition GLP-1 Medications Zepbound Eli Lilly Zepbound Clinical Trials Viking Therapeutics Mounjaro Mounjaro and Zepbound GLP-1 Treatments Telehealth Orforglipron Compounded Drugs Tirzepatide Ozempic Compounded Semaglutide Roche Novo Nordisk A/S Compounded Medications

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

European Commission approval would create the first oral GLP‑1 for adult weight management with pricing left to EU Member States.

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Novo Nordisk Lifts Outlook After Wegovy Pill Fuels Q1 Beat

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength